<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263197</url>
  </required_header>
  <id_info>
    <org_study_id>12598</org_study_id>
    <secondary_id>H9P-EW-LNCI</secondary_id>
    <nct_id>NCT01263197</nct_id>
  </id_info>
  <brief_title>A Study of LY2216684 in Healthy Subjects Receiving Albuterol or Propanolol</brief_title>
  <official_title>Effect of LY2216684 on Heart Rate and Blood Pressure in Healthy Subjects Receiving Oral Doses of Albuterol or Propranolol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of LY2216684 on heart rate of healthy
      people receiving Albuterol and Propranolol. Information about any side effects that may occur
      will also be collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum, minimum and average changes in heart rate</measure>
    <time_frame>Baseline, Day 1, 3 and 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum, minimum and average changes in blood pressure</measure>
    <time_frame>Baseline, Day 1, 3, and 5</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>LY2216684, albuterol, LY221684+albuterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a 7 day washout between each intervention period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>albuterol, LY2216684+albuterol, LY2216684</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in third intervention period. There is a 7 day washout between each intervention period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2216684+albuterol, LY2216684, albuterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in second intervention period, Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a 7 day washout between each intervention period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2216684, propranolol, LY2216684+propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a 7 day washout between each intervention period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propranolol, LY2216684+propranolol, LY2216684</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in third intervention period. There is a 7 day washout between each intervention period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2216684+propranolol, LY2216684, propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in second intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a 7 day washout between each intervention period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2216684</intervention_name>
    <description>administered orally</description>
    <arm_group_label>LY2216684, albuterol, LY221684+albuterol</arm_group_label>
    <arm_group_label>albuterol, LY2216684+albuterol, LY2216684</arm_group_label>
    <arm_group_label>LY2216684+albuterol, LY2216684, albuterol</arm_group_label>
    <arm_group_label>LY2216684, propranolol, LY2216684+propranolol</arm_group_label>
    <arm_group_label>propranolol, LY2216684+propranolol, LY2216684</arm_group_label>
    <arm_group_label>LY2216684+propranolol, LY2216684, propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol</intervention_name>
    <description>administered orally</description>
    <arm_group_label>LY2216684, albuterol, LY221684+albuterol</arm_group_label>
    <arm_group_label>albuterol, LY2216684+albuterol, LY2216684</arm_group_label>
    <arm_group_label>LY2216684+albuterol, LY2216684, albuterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propranolol</intervention_name>
    <description>administered orally</description>
    <arm_group_label>LY2216684, propranolol, LY2216684+propranolol</arm_group_label>
    <arm_group_label>propranolol, LY2216684+propranolol, LY2216684</arm_group_label>
    <arm_group_label>LY2216684+propranolol, LY2216684, propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for LY2216684</intervention_name>
    <description>administered orally</description>
    <arm_group_label>LY2216684, albuterol, LY221684+albuterol</arm_group_label>
    <arm_group_label>albuterol, LY2216684+albuterol, LY2216684</arm_group_label>
    <arm_group_label>LY2216684+albuterol, LY2216684, albuterol</arm_group_label>
    <arm_group_label>LY2216684, propranolol, LY2216684+propranolol</arm_group_label>
    <arm_group_label>propranolol, LY2216684+propranolol, LY2216684</arm_group_label>
    <arm_group_label>LY2216684+propranolol, LY2216684, propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for albuterol</intervention_name>
    <description>administered orally</description>
    <arm_group_label>LY2216684, albuterol, LY221684+albuterol</arm_group_label>
    <arm_group_label>albuterol, LY2216684+albuterol, LY2216684</arm_group_label>
    <arm_group_label>LY2216684+albuterol, LY2216684, albuterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for propranolol</intervention_name>
    <description>administered orally</description>
    <arm_group_label>LY2216684, propranolol, LY2216684+propranolol</arm_group_label>
    <arm_group_label>propranolol, LY2216684+propranolol, LY2216684</arm_group_label>
    <arm_group_label>LY2216684+propranolol, LY2216684, propranolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy, as determined by medical history and physical examination.

          -  Male subjects - Agree to use a reliable method of birth control during the study and
             for 1 month following the last dose of study drug.

          -  Female subjects - Are women of child-bearing potential who test negative for pregnancy
             at the time of enrollment, have used a reliable method of birth control for 6 weeks
             prior to administration of study drug, and agree to use a reliable method of birth
             control during the study and for 1 month following the last dose of study drug; or
             Women not of child-bearing potential due to surgical sterilization (hysterectomy or
             bilateral oophorectomy or tubal ligation) or menopause (at least 1 year without menses
             or 6 months without menses and a follicle stimulating hormone [FSH] &gt;40 mIU/mL).

          -  Have a body weight &gt;50 kg.

          -  Have clinical laboratory test results within normal reference range for the population
             or investigator site, or results with acceptable deviations that are judged to be not
             clinically significant by the investigator.

          -  Have venous access sufficient to allow blood sampling as per the protocol.

          -  Have normal blood pressure and pulse rate (sitting position) as determined by the
             investigator.

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures.

          -  Have given written informed consent approved by Lilly and the ethical review board
             (ERB) governing the site.

        Exclusion Criteria:

          -  Are currently enrolled in, or discontinued within the last 30 days from, a clinical
             trial involving an investigational drug or device or off-label use of a drug or device
             other than the study drug, or are concurrently enrolled in any other type of medical
             research judged not to be scientifically or medically compatible with this study.

          -  Have known allergies to LY2216684, albuterol (Group 1 only), propranolol (Group 2
             only), or related compounds.

          -  Are persons who have previously completed or withdrawn from this study or any other
             study investigating LY2216684 within 6 months prior to screening.

          -  Have an abnormality in the 12-lead ECG that, in the opinion of the investigator,
             increases the risks associated with participating in the study.

          -  Have a history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data.

          -  Have a history of or current asthma, including exercised induce asthma.

          -  Have a history or show evidence of significant active neuropsychiatric disease or have
             a history of suicide attempt or ideation.

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening.

          -  Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV
             antibodies.

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody.

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen.

          -  Are women with a positive pregnancy test or women who are lactating.

          -  Intend to use over-the-counter or prescription medication (including hormonal
             contraceptives) within 14 days prior to dosing unless deemed acceptable by the
             investigator and Sponsor's medical monitor

          -  Have donated blood of more than 500 mL within the last month.

          -  Have an average weekly alcohol intake that exceeds 14 units per week, or are unwilling
             to stop alcohol consumption 48 hours prior to check-in in each period and while
             resident at the CRU (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz
             or 45 mL of distilled spirits).

          -  Consume 5 or more cups of coffee (or other beverages of comparable caffeine content)
             per day, on a habitual basis, or any subjects unwilling to adhere to study caffeine
             restrictions.

          -  Have used any tobacco-containing or nicotine-containing products (including but not
             limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine
             lozenges, or nicotine gum) within 6 months prior to enrollment.

          -  Have consumed grapefruit or grapefruit-containing products 7 days prior to enrollment
             and during the study.

          -  Have a documented or suspected history of glaucoma.

          -  Subjects determined to be unsuitable by the investigator for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2010</study_first_posted>
  <last_update_submitted>April 15, 2011</last_update_submitted>
  <last_update_submitted_qc>April 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Phenylethyl Alcohol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 17, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>March 26, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

